

SECTION 1: IDENTIFICATION

1.1. Product Identifier

Product Form: Mixture

Product Name: VESicare® (solifenacin succinate) Tablets

Material Name: Solifenacin Succinate

CAS No: 242478-38-2

Chemical Formula of Active Ingredient: C₂₃H₂₆N₂O₂ • C₄H₆O₄

Chemical Name of Active Ingredient: butanedioic acid, compounded with (1S)-(3R)-1-azabicyclo[2.2.2]oct-3-yl,3,4-dihydro-1-phenyl-2(1H)-iso-quinolinecarboxylate

1.2. Intended Use of the Product

Use of the substance/mixture: A muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. For professional use only.

1.3. Name, Address, and Telephone of the Responsible Party

Company

Astellas US LLC

1 Astellas Way

Northbrook, IL 60062

Tel.: 800-888-7704

www.us.astellas.com

1.4. Emergency Telephone Number

Emergency Number : 800-727-7003 Medical Communications

SECTION 2: HAZARDS IDENTIFICATION

This product is a drug, as defined by the US Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.) It is in solid, final form for direct administration to the patient. Therefore, is it exempt from the US 2012 Hazard Communication Standard, as defined in the 29 CFR 1910.1200(b)(5)(iii).

SECTION 3: COMPOSITION/INFORMATION ON INGREDIENTS

This product is a drug, as defined by the US Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.) It is in solid, final form for direct administration to the patient. Therefore, is it exempt from the US 2012 Hazard Communication Standard, as defined in the 29 CFR 1910.1200(b)(5)(iii).

SECTION 4: FIRST AID MEASURES

4.1. Description of First Aid Measures

First-aid Measures General: Never give anything by mouth to an unconscious person. If you feel unwell, seek medical advice (show the label if possible).

First-aid Measures After Inhalation: Remove to fresh air and keep at rest in a position comfortable for breathing. Obtain medical attention if breathing difficulty persists.

First-aid Measures After Skin Contact: Gently wash with plenty of soap and water. Obtain medical attention if irritation develops or persists.

First-aid Measures After Eye Contact: Rinse cautiously with water for at least 15 minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Obtain medical attention.

First-aid Measures After Ingestion: Do not induce vomiting. Rinse mouth. Immediately call a POISON CENTER or doctor/physician.

4.2. Most important symptoms and effects, both acute and delayed

Symptoms/Injuries: Pharmaceutical. When handling in workplace settings, in quantities that are most likely above the therapeutic dose, this product may be harmful if absorbed through the eyes, skin, or respiratory tract.

Symptoms/Injuries After Inhalation: If tablet is crushed: May cause respiratory irritation.

Symptoms/Injuries After Skin Contact: If tablet is crushed: May cause skin irritation.

Symptoms/Injuries After Eye Contact: If tablet is crushed: May cause eye irritation.

Symptoms/Injuries After Ingestion: Dry mouth, constipation, blurred vision, (accommodation abnormalities), urinary retention, dry eyes.

Chronic Symptoms: Suspected of damaging the unborn child.

4.3. Indication of Any Immediate Medical Attention and Special Treatment Needed

If you feel unwell, seek medical advice (show the label where possible).

SECTION 5: FIRE-FIGHTING MEASURES

5.1. Extinguishing Media

Suitable Extinguishing Media: Alcohol-resistant foam. Water spray.

VESicare® (solifenacin succinate) Tablets

Safety Data Sheet

According to Federal Register / Vol. 77, No. 58 / Monday, March 26, 2012 / Rules and Regulations

Unsuitable Extinguishing Media: Do not use carbon dioxide or dry chemical. Do not use a heavy water stream. Use of heavy stream of water may spread fire.

5.2. Special Hazards Arising From the Substance or Mixture

Fire Hazard: Not considered flammable but may burn at high temperatures.

Explosion Hazard: Product is not explosive.

Reactivity: Hazardous reactions will not occur under normal conditions.

5.3. Advice for Firefighters

Precautionary Measures Fire: WARNING: Packaging is combustible. Exercise caution when fighting any chemical fire.

Firefighting Instructions: Use water spray or fog for cooling exposed containers.

Protection During Firefighting: Do not enter fire area without proper protective equipment, including respiratory protection.

Other Information: Refer to Section 9 for flammability properties.

SECTION 6: ACCIDENTAL RELEASE MEASURES

6.1. Personal Precautions, Protective Equipment and Emergency Procedures

General Measures: Use only as directed.

6.1.1. For Non-emergency Personnel

Protective Equipment: Use appropriate personal protection equipment (PPE).

Emergency Procedures: Evacuate unnecessary personnel.

6.1.2. For Emergency Responders

Protective Equipment: Equip cleanup crew with proper protection.

Emergency Procedures: Upon arrival at the scene, a first responder is expected to recognize the presence of dangerous goods, protect oneself and the public, secure the area, and call for the assistance of trained personnel as soon as conditions permit.

6.2. Environmental Precautions

Prevent entry to sewers and public waters. Notify authorities if product enters sewers or public waters.

6.3. Methods and Material for Containment and Cleaning Up

For Containment: Contain and collect as any solid.

Methods for Cleaning Up: Clean up spills immediately and dispose of waste safely. Sweep spilled substance into containers; if appropriate, moisten first to prevent dusting. Contact competent authorities after a spill.

6.4. Reference to Other Sections

See Heading 8. Exposure controls and personal protection. For further information refer to section 13.

SECTION 7: HANDLING AND STORAGE

7.1. Precautions for Safe Handling

Additional Hazards When Processed: Avoid breaking or crushing capsules.

Hygiene Measures: Handle in accordance with good industrial hygiene and safety procedures. Wash hands and other exposed areas with mild soap and water before eating, drinking or smoking and when leaving work.

7.2. Conditions for Safe Storage, Including Any Incompatibilities

Technical Measures: Comply with applicable regulations.

Storage Conditions: Store in a dry, cool and well-ventilated place. Keep container closed when not in use. Keep/Store away from direct sunlight, extremely high or low temperatures and incompatible materials.

Incompatible Products: Strong acids, strong bases, strong oxidizers.

Storage Temperature: 25 °C (77 °F); excursions permitted from 15°C to 30°C (59° to 86°F).

7.3. Specific End Use(s)

A muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. For professional use only.

SECTION 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1. Control Parameters

For substances listed in section 3 that are not listed here, there are no established exposure limits from the manufacturer, supplier, importer, or the appropriate advisory agency including: ACGIH (TLV), NIOSH (REL), or OSHA (PEL).

Starch (9005-25-8)		
USA ACGIH	ACGIH TWA (mg/m ³)	10 mg/m ³
USA ACGIH	ACGIH chemical category	Not Classifiable as a Human Carcinogen
USA NIOSH	NIOSH REL (TWA) (mg/m ³)	10 mg/m ³ (total dust) 5 mg/m ³ (respirable dust)
USA OSHA	OSHA PEL (TWA) (mg/m ³)	15 mg/m ³ (total dust) 5 mg/m ³ (respirable fraction)

VESicare[®] (solifenacin succinate) Tablets

Safety Data Sheet

According to Federal Register / Vol. 77, No. 58 / Monday, March 26, 2012 / Rules and Regulations

Titanium dioxide (13463-67-7)		
USA ACGIH	ACGIH TWA (mg/m ³)	10 mg/m ³
USA ACGIH	ACGIH chemical category	Not Classifiable as a Human Carcinogen
USA IDLH	US IDLH (mg/m ³)	5000 mg/m ³
USA OSHA	OSHA PEL (TWA) (mg/m ³)	15 mg/m ³ (total dust)
Iron oxide (Fe ₂ O ₃) (1309-37-1)		
USA ACGIH	ACGIH TWA (mg/m ³)	5 mg/m ³ (respirable fraction)
USA ACGIH	ACGIH chemical category	Not Classifiable as a Human Carcinogen
USA NIOSH	NIOSH REL (TWA) (mg/m ³)	5 mg/m ³ (dust and fume)
USA IDLH	US IDLH (mg/m ³)	2500 mg/m ³ (dust and fume)
USA OSHA	OSHA PEL (TWA) (mg/m ³)	10 mg/m ³ (fume) 15 mg/m ³ (total dust) 5 mg/m ³ (respirable fraction)
Talc (14807-96-6)		
USA ACGIH	ACGIH TWA (mg/m ³)	2 mg/m ³ (particulate matter containing no asbestos and <1% crystalline silica, respirable fraction)
USA ACGIH	ACGIH chemical category	Not Classifiable as a Human Carcinogen containing no asbestos fibers
USA NIOSH	NIOSH REL (TWA) (mg/m ³)	2 mg/m ³ (containing no Asbestos and <1% Quartz-respirable dust)
USA IDLH	US IDLH (mg/m ³)	1000 mg/m ³ (containing no asbestos and <1% quartz)

8.2. Exposure Controls

Appropriate Engineering Controls

: Ensure adequate ventilation, especially in confined areas. Emergency eye wash fountains and safety showers should be available in the immediate vicinity of any potential exposure. Ensure all national/local regulations are observed.

Personal Protective Equipment

: Not generally required. The use of personal protective equipment may be necessary as conditions warrant.

Materials for Protective Clothing

: Chemically resistant materials and fabrics.

Hand Protection

: Wear chemically resistant protective gloves.

Eye Protection

: Chemical goggles or safety glasses.

Skin and Body Protection

: Wear suitable protective clothing.

Respiratory Protection

: None required under normal product handling conditions. Use NIOSH-approved dust mask if dust has the potential to become airborne.

Environmental Exposure Controls

: Do not allow the product to be released into the environment.

Consumer Exposure Controls

: Do not eat, drink or smoke during use.

SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1. Information on Basic Physical and Chemical Properties

Physical State

: Solid

Appearance

: **5 mg:** light yellow tablet branded with a logo and "150" on the tablet body.

10 mg: light pink tablet branded with a logo and "151" on the tablet body.

Odor

: No data available

Odor Threshold

: No data available

pH

: No data available

Evaporation Rate

: No data available

Melting Point

: 144 - 149 °C (291 - 300 °F)

Freezing Point

: No data available

Boiling Point

: No data available

Flash Point

: No data available

Auto-ignition Temperature

: No data available

Decomposition Temperature

: No data available

Flammability (solid, gas)

: No data available

Vapor Pressure

: No data available

VESicare[®] (solifenacin succinate) Tablets

Safety Data Sheet

According to Federal Register / Vol. 77, No. 58 / Monday, March 26, 2012 / Rules and Regulations

Relative Vapor Density at 20 °C	: No data available
Relative Density	: No data available
Solubility	: 610 mg/mL; freely soluble at room temperature in water, glacial acetic acid, dimethyl sulfoxide, and methanol
Partition Coefficient: N-Octanol/Water	: No data available
Viscosity	: No data available
Molecular Weight Of Active Ingredient	: 480.55 g/mol

9.2. Other Information No additional information available

SECTION 10: STABILITY AND REACTIVITY

- 10.1. **Reactivity:** Hazardous reactions will not occur under normal conditions.
- 10.2. **Chemical Stability:** Stable under recommended handling and storage conditions (see section 7).
- 10.3. **Possibility of Hazardous Reactions:** Hazardous polymerization will not occur.
- 10.4. **Conditions to Avoid:** Direct sunlight. Extremely high or low temperatures. Ignition sources. Incompatible materials.
- 10.5. **Incompatible Materials:** Strong acids, strong bases, strong oxidizers.
- 10.6. **Hazardous Decomposition Products:** Carbon oxides (CO, CO₂). Nitrogen oxides.

SECTION 11: TOXICOLOGICAL INFORMATION

11.1. Information On Toxicological Effects

Acute Toxicity: Not classified

Cellulose hydroxypropyl methyl ether (9004-65-3)	
LD50 Oral Rat	>= 4000 mg/kg
Magnesium stearate (557-04-0)	
LD50 Oral Rat	> 2000 mg/kg
Titanium dioxide (13463-67-7)	
LD50 Oral Rat	> 10000 mg/kg
Iron oxide (Fe2O3) (1309-37-1)	
LD50 Oral Rat	> 10000 mg/kg
Polyethylene glycol (25322-68-3)	
LD50 Oral Rat	47000 mg/kg
LD50 Dermal Rabbit	> 20 ml/kg

Skin Corrosion/Irritation: Not classified

Serious Eye Damage/Irritation: Not classified

Respiratory or Skin Sensitization: Not classified

Germ Cell Mutagenicity: Not classified

Solifenacin succinate (242478-38-2)	
Additional information	Solifenacin succinate was not mutagenic in the <i>in vitro</i> <i>Salmonella typhimurium</i> or <i>Escherichia coli</i> microbial mutagenicity test or chromosomal aberration test in human peripheral blood lymphocytes with or without metabolic activation, or in the <i>in vivo</i> micronucleus test in rats.

Carcinogenicity: Not classified

Solifenacin succinate (242478-38-2)	
Additional information	No increase in tumors was found following the administration of solifenacin succinate to male and female mice for 104 weeks at doses up to 200 mg/kg/day (5 and 9 times human exposure at the maximum recommended human dose [MRHD], respectively), and male and female rats for 104 weeks at doses up to 20 and 15 mg/kg/day, respectively (<1 times exposure at the MRHD).

Titanium dioxide (13463-67-7)	
IARC group	2B
OSHA Hazard Communication Carcinogen List	In OSHA Hazard Communication Carcinogen list.
Iron oxide (Fe2O3) (1309-37-1)	
IARC group	3
Talc (14807-96-6)	
IARC group	3

VESicare[®] (solifenacin succinate) Tablets

Safety Data Sheet

According to Federal Register / Vol. 77, No. 58 / Monday, March 26, 2012 / Rules and Regulations

National Toxicology Program (NTP) Status	Evidence of Carcinogenicity, Twelfth Report - Items under consideration.
---	--

Reproductive Toxicity: Suspected of damaging the unborn child.

Solifenacin succinate (242478-38-2)	
Additional information	<p>Solifenacin succinate had no effect on reproductive function, fertility or early embryonic development of the fetus in male and female mice treated with 250 mg/kg/day (13 times exposure at the MRHD) of solifenacin succinate, and in male rats treated with 50 mg/kg/day (<1 times exposure at the MRHD) and female rats treated with 100 mg/kg/day (1.7 times exposure at the MRHD) of solifenacin succinate.</p> <p>Reproduction studies have been performed in mice, rats and rabbits. After oral administration of ¹⁴C-solifenacin succinate to pregnant mice, drug-related material was shown to cross the placental barrier. No embryotoxicity or teratogenicity was observed in mice treated with 30 mg/kg/day (1.2 times exposure at the maximum recommended human dose [MRHD]). Administration of solifenacin succinate to pregnant mice at doses of 100 mg/kg and greater (3.6 times exposure at the MRHD), during the major period of organ development resulted in reduced fetal body weights. Administration of 250 mg/kg (7.9 times exposure at the MRHD) to pregnant mice resulted in an increased incidence of cleft palate. In utero and lactational exposures to maternal doses of solifenacin succinate of 100 mg/kg/day and greater (3.6 times exposure at the MRHD) resulted in reduced peripartum and postnatal survival, reductions in body weight gain, and delayed physical development (eye opening and vaginal patency).</p> <p>An increase in the percentage of male offspring was also observed in litters from offspring exposed to maternal doses of 250 mg/kg/day. No embryotoxic effects were observed in rats at up to 50 mg/kg/day (<1 times exposure at the MRHD) or in rabbits at up to 50 mg/kg/day (1.8 times exposure at the MRHD). There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, solifenacin succinate should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>

Specific Target Organ Toxicity (Single Exposure): Not classified

Specific Target Organ Toxicity (Repeated Exposure): Not classified

Aspiration Hazard: Not classified

Symptoms/Injuries After Inhalation: If tablet is crushed: May cause respiratory irritation.

Symptoms/Injuries After Skin Contact: If tablet is crushed: May cause skin irritation.

Symptoms/Injuries After Eye Contact: If tablet is crushed: May cause eye irritation.

Symptoms/Injuries After Ingestion: Dry mouth, constipation, blurred vision, (accomodation abnormalities), urinary retention, dry eyes.

Chronic Symptoms: Suspected of damaging the unborn child.

SECTION 12: ECOLOGICAL INFORMATION

12.1. Toxicity

Talc (14807-96-6)	
LC50 Fish 1	> 100 g/l (Exposure time: 96 h - Species: Brachydanio rerio [semi-static])

12.2. Persistence and Degradability No additional information available.

12.3. Bioaccumulative Potential

Talc (14807-96-6)	
BCF fish 1	(no known bioaccumulation)

12.4. Mobility in Soil No additional information available.

12.5. Other Adverse Effects

Other Information : Avoid release to the environment.

VESicare[®] (solifenacin succinate) Tablets

Safety Data Sheet

According to Federal Register / Vol. 77, No. 58 / Monday, March 26, 2012 / Rules and Regulations

SECTION 13: DISPOSAL CONSIDERATIONS

13.1. Waste treatment methods

Waste Disposal Recommendations: Dispose of contents and container according to local, regional, national, and international regulations.

Ecology – Waste Materials: Avoid release to the environment.

SECTION 14: TRANSPORT INFORMATION

14.1. In Accordance with DOT Not regulated for transport.

14.2. In Accordance with IMDG Not regulated for transport.

14.3. In Accordance with IATA Not regulated for transport.

SECTION 15: REGULATORY INFORMATION

15.1 US Federal Regulations Not applicable

15.2 US State Regulations Not applicable

SECTION 16: OTHER INFORMATION, INCLUDING DATE OF PREPARATION OR LAST REVISION

Revision Date : 06/10/2015

Other Information : This document has been prepared in accordance with the SDS requirements of the OSHA Hazard Communication Standard 29 CFR 1910.1200.

This information is based on our current knowledge and is intended to describe the product for the purposes of health, safety and environmental requirements only. It should not therefore be construed as guaranteeing any specific property of the product.

Astellas US GHS SDS